Lymphoma

The EORTC-1537-COBRA trial investigated the efficacy of very early FDG-PET/CT response-adapted therapy in patients with advanced-stage Hodgkin lymphoma using brentuximab vedotin-containing regimens, i.e. brentuximab vedotin, doxorubicin, vinblastine and dacarbazine (A-AVD); and brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (BrECADD). This phase II study enrolled 150 patients, all of whom received an initial cycle of A-AVD, followed by an early PET/CT scan. Patients with negative PET results (Deauville scores 1–3) continued with A-AVD, while those with positive results (scores 4–5) switched to BrECADD. Radiotherapy was given only to those with residual PET positivity after chemotherapy.

The Renoir phase 3 study investigates the efficacy of combining rituximab and lenalidomide versus rituximab alone for relapsed/refractory (R/R) follicular lymphoma in elderly patients, in whom treatment options are typically limited. Lenalidomide, known for its direct anti-tumor and antiangiogenic effects, and ability to modulate the tumor-cell microenvironment, presents a viable option, and when combined with […]

Dr Anna Sureda, President of the European Society for Blood and Marrow Transplantation (EBMT), summarizes the main take-home messages from her educational session on the latest improvements in autologous stem cell transplantation for patients with Hodgkin lymphoma. These include the introduction of new drugs in the salvage setting such as checkpoint inhibitors, improvements to long-term […]

CAR-T cell therapy and bispecifics in the treatment of lymphoma: Updates from ASH 2022 Prof. Swaminathan Iyer (University of Texas MD Anderson Cancer Center) reviews the latest data around CAR-T cell therapy and bispecific antibodies presented at ASH 2022. Further information: Abstract 655 entitled ‘Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy […]

The role of transplant and biologics in mantle cell lymphoma In the first of two updates from ASH 2022, Swaminathan Iyer (University of Texas MD Anderson Cancer Center) provides an overview of the plenary session presented by Dr Martin Dreyling at ASH 2022, discussing the role of transplant and biologics in mantle cell lymphoma. In […]